NCPIC

Great illustration of the power of PET/CT visualizing prostate cancer with accurate precision. In this educational example, NCPIC imaging discovered: “Stage 1 PSMA Exam Finding: Male with new diagnosis of prostate cancer, Gleason score 3 + 3, PSA 6.10. PSMA PET CT shows one focus of abnormal tracer activity confined to the left prostate lobe, consistent with biopsy proved cancer. No evidence of PSMA-avid metastasis.” Kudos to the NCPIC care team, led by Medical Director DAFANG Wu, MD, for their great work! —————— Some notes: “Gleason score” helps determine prostate cancer risk level which range from sub-6 to 10. (6 = low 10 = high risk). The prostate gland has a left & right side, so a Gleason score adds together left & right figures. PSA refers to a blood test marker called a prostate specific antigen (“PSA”). Above 2.5 is considered high risk for prostate. #psma #petct #PSA #prostatecancer #cancerawareness #healthcare

Cancer care teams globally use the term “malignant transformation” to describe a cancer type that literally changes from one type of cancer to another - so I wanted to visualize this phenomenon on a type of cancer called “non-Hodgkin’s lymphoma.” In this illustration, a patient was diagnosed with a type of lymphoma called a “low grade follicular lymphoma” and was referred to NCPIC for a baseline PET/CT to help oncology care teams visualize disease location and progress. (Bottom images). Our clinical team felt the follicular lymphoma appeared to have “transformed” - from follicular to “diffused large B-cell lymphoma” - and recommended a new biopsy be performed to confirm lymphoma type; confirming a malignant transformation occurred. The change in clinical information resulted in lymphoma therapy change to “R.I.C.E. Therapy” - and favorable treatment response as visualized on a follow-up PET/CT (top row). Special thanks to great clinical work performed by the NCPIC imaging team and our talented Medical Director DAFANG Wu . Some notes: RICE is an oncology acronym which includes: rituximab, ifosfamide, carboplatin, and etoposide phosphate - all types of therapy agents. Retuximab was created by Genentech Roche and is sold under the drug name “Rituxan”. Malignant transformations occurs about 2% of the cases according to Lymphoma Action. The Leukemia & Lymphoma Society #malignanttransformation #follicular #largebcell #fdg #petct #cancerawareness Oncology Nursing Society

Such a wonderful event.

Just wanted to illustrate the power of modern oncology therapy - visualized at two points in time using FDG PET/CT - to treat a type of cancer called “non-small cell” lung cancer. In this this illustration, a stage IV non-small cell lung cancer patient was treated with an oral chemotherapy agent called TAGRISSO® (osimertinib) HCP, manufactured by AstraZeneca, with imaging technology FDG PET/CT being used to visualize care treatment progress. The improvements are quite dramatic, with NCPIC’s Medical Director DAFANG Wu finding the patient achieved a favorable, but partial, treatment response on their FDG PET/CT exams. Congratulations to the brilliant minds globally working on treatments, such as Tagrisso, and the talented Northern California care oncology care teams advancing cancer care forward. #lungcancerawareness #lungcancer #nonsmallcell #fdg #petct #medicaltechnology #oncology #northerncalifornia #tagrisso #oralversusIV

Great recent post on theranostics and #PSMA #petct medical technology in action.

Great illustration on the power of PET.

Good article from UCLA Health’s prostate imaging program using an imaging agent #psma #petct en lieu of conventional imaging work up (eg #bonescan + #ct). https://lnkd.in/gnh-_rXQ

Looking to support patients with high coinsurance or deductible costs? Look no further than Northern California PET Imaging Center. Our exam rates are up to 80% less expensive than other facilities in the Northern California market (as shown by CPT code 78815), resulting in $17,217 in savings in billed charges amount. This is great news for care teams supporting patient access during the "deductible season." Please contact our team with any questions. #nonprofit #independent #deductible #insurance #oncology

As 2023 comes to and end, the team at Northern Califorina PET Imaging Center wants to send a sincere “thank you” to our patients, customers, clinical providers for their support. Looking forward to supporting care teams in 2024.

Congratulations to the NCPIC team! “Low dose PET” is here in Northern California.